STOCK TITAN

Diffusion Pharmaceuticals Inc. - DFFN STOCK NEWS

Welcome to our dedicated news page for Diffusion Pharmaceuticals (Ticker: DFFN), a resource for investors and traders seeking the latest updates and insights on Diffusion Pharmaceuticals.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Diffusion Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Diffusion Pharmaceuticals's position in the market.

Rhea-AI Summary
Approximately 71% of Stockholders Voted in Favor of the Transaction. Diffusion announces 1-for-1.5 Reverse Stock Split. Merger on track to close on August 16, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.68%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-12.78%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.98%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
14.23%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.4%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.22%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.29%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.4%
Tags
none
Diffusion Pharmaceuticals Inc.

Nasdaq:DFFN

DFFN Rankings

DFFN Stock Data

8.98M
2.03M
0.23%
10.27%
0.12%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Charlottesville

About DFFN

diffusion pharmaceuticals is a clinical stage company focused on improving the effectiveness of standard-of-care therapies for life-threatening treatment-resistant solid cancerous tumors, without adding harmful side effects. the company is developing its lead drug, trans sodium crocetinate (tsc), which has received orphan drug designation from the fda for use in a number of cancers in which tumor hypoxia (oxygen deprivation) diminishes the efficacy of current treatments. tsc targets the cancer’s hypoxic micro-environment, re-oxygenating treatment-resistant tissue and making the cancerous cells more vulnerable to the therapeutic effects of conventional radiation and chemotherapy. the company is poised to begin a pivotal phase 3 trial in glioblastoma (gbm) in 2016. other programs include planned phase 2/3 trials in pancreatic cancer and brain metastases. because tsc’s novel mechanism safely re-oxygenates a wide range of tumor types, its use is not limited to a specific tumor tissue, but